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operates in a number of them and 
earns there only around £30 million.
Despite the concerns, many still 
believe Witty’s pledge marks a major 
step forward for neglected diseases 
and developing countries. “He is 
breaking the mould in validating 
the concept of patent pools,” said 
Rohit Malpani at Oxfam’s access to 
medicines campaign. “It is a big step 
forward. It is welcome that he is inviting 
other companies to take this on.”
But positive moves in the 
development of medicines by 
freeing up patents by GSK in certain 
areas is not a signal for a wider 
loosening on intellectual property. If 
anything, Europe is getting tougher in 
protecting its patents. The EU’s trade 
commissioner, Catherine Ashton, 
is currently pushing developing 
countries to accept stringent 
provisions on intellectual property. 
This goal “prioritises the rights of 
patent holders at the expense of 
access to medicines, jeopardising 
health in developing countries,” writes 
Monika Kosininska, secretary-general 
of the European Public Health Alliance 
in a letter to The Guardian. 
“The European Commission has 
made commitments in multilateral 
fora, such as the WHO and the WTO’s 
2001 Doha declaration, to support 
health in developing countries. The 
behaviour of Ashton undermines these 
commitments,” she says.
not win him many friends in the other 
drug companies,” but he hoped they 
would join him in an effort to make a 
significant difference to the health of 
people in poor countries.
Médecins Sans Frontières, a leading 
health NGO, says Witty’s price cut for 
drugs is welcome but not a panacea 
for availability of drugs. And the 
charity is also disappointed that HIV/
Aids patents have not been included 
in the proposed patent pool.
The charity World Vision’s director 
of advocacy, Mike French, said: 
“Slashing drug prices is good. 
But, without the necessary health 
infrastructure, many won’t be able 
to access those drugs. Therefore, 
investment by GSK, along with the 
knowledge pooling, makes this a 
landmark announcement.”
Drug companies are criticised for 
failing to deliver for the rich world 
as well as the poor. They are often 
accused of focusing their efforts on 
making barely altered copies of other 
companies’ billion-dollar sellers rather 
than working on diseases where 
there are few treatments, such as 
Alzheimer’s.
Critics of the drug companies 
acknowledged that in these moves 
GSK was making major strides but 
said that it could go further: promising 
20 per cent of profits from sales in the 
least developed countries does not 
amount to a huge sum as GSK only 
Shifting: Andrew Witty, chief executive of the pharmaceutical company GSK last month an-
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Have you always been interested 
in biology? I can’t remember a time 
when I wasn’t interested in biology, 
particularly animal behavior and 
evolution. My family lived in rural 
Ohio when I was four or five years 
old, and I recall spending a lot of time 
outdoors watching hummingbirds 
around the big spruce trees next to 
our house. A more formative moment 
was when my mother took me to 
the Cleveland Museum of Natural 
History and I had the chance to see 
the ‘Lucy’ skeleton (Australopithecus 
afarensis) — at that time the earliest 
known hominid specimen. This was 
a truly transformative experience, 
and generated an intense obsession 
with primate and human evolution, 
altogether at odds with my strict 
Catholic upbringing. Throughout 
childhood, I kept a set of Time-Life 
books on ‘Evolution’, ‘The Primates’, 
and ‘Animal Behavior’ under my bed 
to read each night before going to 
Q & A
Magazine
R183sleep. Unfortunately, the local public 
schools were not so welcoming 
towards my interests in evolutionary 
biology; the conspicuous absence of 
any teaching of evolution nearly drove 
me away from biology. 
What is the best advice you’ve been 
given? Probably the best advice I’ve 
ever been given was from my father, 
who was uniquely gifted in many ways 
but who, through bad luck and an 
obsession with bridge and fast cars, 
ended up dropping out of college 
and working as an auto mechanic. 
Despite clearly working beneath his 
potential, he always encouraged me to 
follow my passions and not to worry 
about choosing a career just to make 
money. Coming from a guy who toiled 
tirelessly under the hood of a car all 
day, this wisdom deeply influenced 
me. And I’ve tried to follow this advice 
throughout my career by following my 
interests — from human evolution to 
primate behavior to neuroscience and 
back again. 
What advice would you offer to 
someone starting a career in 
biology? Evolution often favors 
generalists over specialists; witness 
the success of rats, cockroaches, and 
rhesus macaques. Students would 
be wise to follow suit. They should 
read and study widely, not only within 
science, but also in literature and the 
arts. After all, the most interesting 
questions for biologists are those that 
pertain to what makes us uniquely 
human, and how our brains enable this 
behavior. To pursue these questions 
one needs an appreciation for how 
really smart people, who are not 
scientists, have approached the same 
problems. My other really strong 
recommendation is that students 
learn to write effectively, and practice 
writing often. Science depends 
on clear communication, both to 
other scientists and perhaps more 
importantly to the public at large. 
What role has chance played in 
your scientific career? I wouldn’t 
be where I am today without a lot 
of luck. I lucked into going to Yale, 
first as a football recruit and then 
later supported by a fellowship from 
Cleveland alumni. I lucked into meeting 
and learning from so many important 
people in the fields of primate behavior 
and neuroscience early in my career. 
My first semester at Yale, I happened to take a course on Primate Evolution, 
given by Mark Birchette — the best 
teacher I’ve ever had — and his course 
re-ignited my passion for biology. 
Probably the luckiest moment of 
my scientific and personal life was 
meeting my future wife, Elizabeth 
Brannon, a current leader in the field 
of primate cognition, while we were 
studying stumptail macaques on 
an island in Mexico during college. 
That field experience led me to the 
University of Pennsylvania for graduate 
work in primate behavior with Dorothy 
Cheney, Robert Seyfarth, and Robert 
Harding. A disastrous field season 
spent looking for, and not finding, 
capuchin monkeys in Venezuela, 
complete with an attack by a swarm 
of sweat bees, convinced me that my 
temperament was better suited to 
work in the laboratory. 
Subsequently, I joined Paul 
Glimcher’s lab at NYU for post-
doctoral training in neuroscience. 
Coincidentally, Paul had done 
his thesis work at the University 
of Pennsylvania and knew my 
advisors well, so he was willing to 
take a gamble on me despite my 
having absolutely no experience in 
neurophysiology; and I was willing 
to gamble on him because he was 
interested in primate behavior 
and promised me that, once I had 
learned the tools, I could actually do 
something unique and interesting in 
neuroscience. I spent two dull years 
studying the role of the parietal cortex 
in eye movements, while Paul and I 
began hatching a new set of studies 
aimed at applying behavioral economic 
models to the neurobiology of decision 
making. After our paper on the ‘Neural 
correlates of decision variables in 
parietal cortex’ was published in 
Nature in 1999, I was lucky enough 
to land a job at Duke that gave me 
the freedom to pursue my interests in 
neuroethology and neuroeconomics.
What are your favorite papers or 
books? Several papers and books 
have been extremely important in my 
intellectual development. Darwin’s 
great trilogy — The Origin of Species, 
Descent of Man and Selection in 
Relation to Sex, and The Expression of 
the Emotions in Man and Animals — 
has provided important inspiration for 
my work. Eric Charnov’s paper on the 
Marginal Value Theorem for patch-
leaving decisions by foraging animals 
really blew my mind, convincing me that formal mathematical models 
can provide a powerful approach for 
predicting and explaining behavior. 
Robert Trivers’ seminal papers on 
reciprocal altruism and parental 
investment demonstrated that the 
same formal, mathematical approach 
could be applied to the evolution of 
social behavior. Randy Gallistel’s The 
Organization of Learning prompted me 
to think about how the fundamental 
challenges of navigation and foraging 
in space and time may be solved 
by representing information about 
the environment rather than simply 
potentiating stimulus–response 
associations. The neuroscience paper 
that has had the biggest influence on 
me was probably Bill Newsome and 
Mike Shadlen’s on motion perception 
and decision making — that paper 
really got people thinking about how to 
study the neurobiology of choice.
What do you see as the biggest 
challenge confronting progress 
in cognitive neuroscience? My 
own bias is that neuroscience today 
largely avoids thinking about brain 
and behavior from an evolutionary 
perspective. Although there is some 
consideration given to homology 
in brain structure — for example, 
rhesus macaques and humans 
clearly share multiple visual 
processing areas due to common 
descent — the idea that specialized 
neural hardware may have evolved 
to support specialized behavior and 
cognition is often given short shrift. 
Thus, rhesus monkeys often serve 
as a model for understanding human 
neurophysiology, and mice serve as 
a model for exploring the genetics 
that contribute to human behavior 
and cognition. But this approach fails 
to account for the unique problems 
each species has had to confront 
over its evolutionary history. In order 
to understand human nature, we’ll 
need to understand the comparative 
biology and behavior of a wide 
range of primates — specifically how 
different species of primates have 
adapted to particular social and 
environmental conditions. We may find 
some surprising differences, and some 
equally shocking similarities, with our 
own brains, genes, and behavior.
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